Mometasone Furoate; Olopatadine Hydrochloride Patent Expiration
Mometasone Furoate; Olopatadine Hydrochloride is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate. It was first introduced by Glenmark Specialty Sa
Mometasone Furoate; Olopatadine Hydrochloride Patents
Given below is the list of patents protecting Mometasone Furoate; Olopatadine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ryaltris | US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis | Sep 03, 2038 | Glenmark Speclt |
| Ryaltris | US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
| Ryaltris | US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | Sep 04, 2034 | Glenmark Speclt |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mometasone Furoate; Olopatadine Hydrochloride's patents.
Latest Legal Activities on Mometasone Furoate; Olopatadine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Mometasone Furoate; Olopatadine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765686 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2024 | US10758550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9370483 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2023 | US10646500 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Aug, 2023 | US10561672 |
| Post Issue Communication - Certificate of Correction | 31 Jul, 2023 | US10016443 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jul, 2023 | US10548907 |
| Electronic Review Critical | 29 Jun, 2023 | US10016443 |
| Email Notification Critical | 29 Jun, 2023 | US10016443 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 28 Jun, 2023 | US10016443 |
Mometasone Furoate; Olopatadine Hydrochloride's Family Patents
